300142:SZSEWalvax Biotechnology Co., Ltd. Class A Analysis

Walvax Biotechnology is trading at CNY 12.19, just above its 20‑day (12.03) and 50‑day (12.07) moving averages, but still below the near‑term resistance of CNY 12.83. Technical signals are mixed: RSI sits at a neutral 52.7, while the MACD line has just crossed above its signal, giving a modest bullish hint. Fundamentally, the stock appears severely overvalued – a trailing P/E of 406 versus an industry average of 26.7, and a DCF‑derived fair value of only CNY 4.25, implying a downside of roughly 42%. Revenue has contracted by 20% year‑over‑year, though margins remain solid (gross margin 67%). The company holds ample cash (CNY 1.68 bn) against modest debt, but earnings are negative, making the 0.34% dividend questionable. Volatility is high at 50.9% over the past month, while beta is low (≈0.31), suggesting market‑wide moves have limited impact but the stock itself is swingy.